John Strickler

Academic History

John Strickler, MD, is a Professor of Medicine in the Division of Medical Oncology at Duke University, Durham, NC, and a Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute, Durham, NC. He is also Leader of the Molecular Tumor Board and Associate Director of Clinical Research-GI Oncology at Duke University. Prof. Strickler received his medical degree at the University of Chicago, Chicago, IL, and completed his residency at the University of Washington, Seattle, WA. He went on to complete a fellowship in Hematology-Oncology at Duke University.

Prof. Strickler has research interests in the design and execution of clinical trials that develop novel therapies for gastrointestinal (GI) cancers. His clinic specializes in the treatment of gastrointestinal tumors, specifically gastroesophageal, colorectal, and pancreatic cancers. He was previously a member of the American Society of Clinical Oncology (ASCO) Treatment Guidelines Committee for Advanced Colon Cancer.

Speaking on clinical trials for gastrointestinal cancers

Prof. Strickler’s research focuses on developing novel therapies for GI cancers through precision cancer medicine, particularly non-invasive testing to identify genetic drivers of treatment resistance in patients. He was a principal investigator for the clinical trial that led to the first FDA-approved drug for HER2+ metastatic colorectal cancer. He was a principal investigator in more than 50 clinical trials, and first-author for publications in oncology journals such as New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. Prof. Strickler served as co-chair of GI Steering Committee for the Academic and Community Cancer Research United (ACCRU) clinical trial consortium.